Kadmon Highlights Recent Progress and Reports Fourth Quarter and Full Year 2019 Financial Results
March 05, 2020 16:14 ET
|
Kadmon Holdings, Inc.
NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year...
Kadmon Announces Appointment of Steven Meehan as CFO
February 11, 2019 16:15 ET
|
Kadmon Holdings, Inc.
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the appointment of Steven Meehan as Executive Vice President, Chief Financial Officer. Mr. Meehan, who...
Kadmon Announces Appointment of David E. Cohen, M.D., MPH, to Board of Directors
February 07, 2019 16:15 ET
|
Kadmon Holdings, Inc.
NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the appointment of David E. Cohen, M.D., MPH, to its Board of Directors. Dr. Cohen has held a variety...
Kadmon Announces Appointment of Cynthia Schwalm to Board of Directors
January 23, 2019 16:15 ET
|
Kadmon Holdings, Inc.
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the appointment of Cynthia Schwalm to its Board of Directors. Ms. Schwalm has extensive pharmaceutical...
Kadmon Announces Appointment of Tasos G. Konidaris as Interim Chairman of the Board
January 04, 2019 16:15 ET
|
Kadmon Holdings, Inc.
NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Tasos G. Konidaris, a member of Kadmon’s board of directors, has been appointed interim chairman,...
Kadmon Chairman Bart M. Schwartz to Step Down from Board
December 27, 2018 16:15 ET
|
Kadmon Holdings, Inc.
NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Bart M. Schwartz, Esq. is stepping down as director and Chairman of the Board of Directors (the...
Kadmon Announces Updated Findings from Ongoing Phase 2 Clinical Trial of KD025 in cGVHD at ASH Annual Meeting
December 03, 2018 10:00 ET
|
Kadmon Holdings, Inc.
NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced updated data from its ongoing Phase 2 clinical trial of KD025, its selective oral inhibitor of...
Kadmon Presents Data on New ROCK Inhibitor Clinical Candidate at Anti-Fibrotic Drug Development Summit
November 29, 2018 09:00 ET
|
Kadmon Holdings, Inc.
NEW YORK, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the presentation of preclinical data supporting the therapeutic potential of Rho-associated coiled-coil...
Kadmon Provides Business Update and Reports Third Quarter 2018 Financial Results
November 09, 2018 16:20 ET
|
Kadmon Holdings, Inc.
NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the third quarter of 2018. “We...
Kadmon to Present at the Jefferies 2018 London Healthcare Conference
November 07, 2018 09:00 ET
|
Kadmon Holdings, Inc.
NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Jefferies 2018...